rhNGF (Cenegermin)
Neurotrophic Keratitis (NK)
Key Facts
About Dompé
Dompé is a mature, global biopharma company transitioning from a traditional pharmaceutical base to a biotech innovation leader. Its core asset is a proprietary recombinant human Nerve Growth Factor (rhNGF), with its first approved product, cenegermin (Oxervate), for neurotrophic keratitis. The company is advancing a pipeline of rhNGF-based therapies into new neurological and ophthalmology indications while commercializing its Exscalate AI/High-Performance Computing platform for external partnerships. With significant R&D investment and a commercial footprint in ~40 countries, Dompé blends deep therapeutic expertise with cutting-edge computational drug discovery.
View full company profileAbout Dompé
Dompé is a mature, global biopharma company transitioning from a traditional pharmaceutical base to a biotech innovation leader. Its core asset is a proprietary recombinant human Nerve Growth Factor (rhNGF), with its first approved product, cenegermin (Oxervate), for neurotrophic keratitis. The company is advancing a pipeline of rhNGF-based therapies into new neurological and ophthalmology indications while commercializing its Exscalate AI/High-Performance Computing platform for external partnerships. With significant R&D investment and a commercial footprint in ~40 countries, Dompé blends deep therapeutic expertise with cutting-edge computational drug discovery.
View full company profileAbout Dompé
Dompé is a mature, global biopharma company transitioning from a traditional pharmaceutical base to a biotech innovation leader. Its core asset is a proprietary recombinant human Nerve Growth Factor (rhNGF), with its first approved product, cenegermin (Oxervate), for neurotrophic keratitis. The company is advancing a pipeline of rhNGF-based therapies into new neurological and ophthalmology indications while commercializing its Exscalate AI/High-Performance Computing platform for external partnerships. With significant R&D investment and a commercial footprint in ~40 countries, Dompé blends deep therapeutic expertise with cutting-edge computational drug discovery.
View full company profileAbout Dompé
Dompé is a mature, global biopharma company transitioning from a traditional pharmaceutical base to a biotech innovation leader. Its core asset is a proprietary recombinant human Nerve Growth Factor (rhNGF), with its first approved product, cenegermin (Oxervate), for neurotrophic keratitis. The company is advancing a pipeline of rhNGF-based therapies into new neurological and ophthalmology indications while commercializing its Exscalate AI/High-Performance Computing platform for external partnerships. With significant R&D investment and a commercial footprint in ~40 countries, Dompé blends deep therapeutic expertise with cutting-edge computational drug discovery.
View full company profile